These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 18046862)

  • 1. Use of Respimat Soft Mist inhaler in COPD patients.
    Anderson P
    Int J Chron Obstruct Pulmon Dis; 2006; 1(3):251-9. PubMed ID: 18046862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient preferences for inhaler devices in chronic obstructive pulmonary disease: experience with Respimat Soft Mist inhaler.
    Hodder R; Price D
    Int J Chron Obstruct Pulmon Dis; 2009; 4():381-90. PubMed ID: 19888356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of the development of Respimat Soft Mist Inhaler.
    Dalby R; Spallek M; Voshaar T
    Int J Pharm; 2004 Sep; 283(1-2):1-9. PubMed ID: 15363496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the aerosol velocity and spray duration of Respimat Soft Mist inhaler and pressurized metered dose inhalers.
    Hochrainer D; Hölz H; Kreher C; Scaffidi L; Spallek M; Wachtel H
    J Aerosol Med; 2005; 18(3):273-82. PubMed ID: 16181002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature.
    Brocklebank D; Ram F; Wright J; Barry P; Cates C; Davies L; Douglas G; Muers M; Smith D; White J
    Health Technol Assess; 2001; 5(26):1-149. PubMed ID: 11701099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Higher lung deposition with Respimat Soft Mist inhaler than HFA-MDI in COPD patients with poor technique.
    Brand P; Hederer B; Austen G; Dewberry H; Meyer T
    Int J Chron Obstruct Pulmon Dis; 2008; 3(4):763-70. PubMed ID: 19281091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review of comparative studies of tiotropium Respimat® and tiotropium HandiHaler® in patients with chronic obstructive pulmonary disease: does inhaler choice matter?
    Dahl R; Kaplan A
    BMC Pulm Med; 2016 Oct; 16(1):135. PubMed ID: 27724909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Respimat
    Iwanaga T; Tohda Y; Nakamura S; Suga Y
    Clin Drug Investig; 2019 Nov; 39(11):1021-1030. PubMed ID: 31377981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical effectiveness of the Respimat inhaler device in managing chronic obstructive pulmonary disease: evidence when compared with other handheld inhaler devices.
    Ram FS; Carvallho CR; White J
    Int J Chron Obstruct Pulmon Dis; 2011; 6():129-39. PubMed ID: 21468167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of ipratropium bromide/fenoterol hydrobromide (Berodual) delivered via Respimat Soft Mist Inhaler in patients with asthma and chronic obstructive pulmonary disease.
    Kässner F; Hodder R; Bateman ED
    Drugs; 2004; 64(15):1671-82. PubMed ID: 15257628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of eco-friendly inhalers: focus on combination ipratropium bromide and albuterol in chronic obstructive pulmonary disease.
    Panos RJ
    Int J Chron Obstruct Pulmon Dis; 2013; 8():221-30. PubMed ID: 23658481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deposition of corticosteroid aerosol in the human lung by Respimat Soft Mist inhaler compared to deposition by metered dose inhaler or by Turbuhaler dry powder inhaler.
    Pitcairn G; Reader S; Pavia D; Newman S
    J Aerosol Med; 2005; 18(3):264-72. PubMed ID: 16181001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhaler usability of a pressurized metered dose inhaler and a soft mist inhaler in patients with COPD: A simulated-use study.
    Ding B; Siddiqui S; DePietro M; Petersson G; Martin UJ
    Chron Respir Dis; 2019; 16():1479972318787914. PubMed ID: 30016880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aerosol Plumes of Inhalers Used in COPD.
    Wachtel H; Emerson-Stadler R; Langguth P; Hohlfeld JM; Ohar J
    Pulm Ther; 2024 Mar; 10(1):109-122. PubMed ID: 38194194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced Environmental Impact of the Reusable Respimat
    Hänsel M; Bambach T; Wachtel H
    Adv Ther; 2019 Sep; 36(9):2487-2492. PubMed ID: 31317391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Technical Evaluation of Soft Mist Inhaler Use in Patients with Chronic Obstructive Pulmonary Disease: A Cross-Sectional Study.
    Zhang W; Xu L; Gao S; Ding N; Shu P; Wang Z; Li Y
    Int J Chron Obstruct Pulmon Dis; 2020; 15():1471-1479. PubMed ID: 32606655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pressurised metered-dose inhalers versus all other hand-held inhalers devices to deliver bronchodilators for chronic obstructive pulmonary disease.
    Ram FS; Brocklebank DM; Muers M; Wright J; Jones PW
    Cochrane Database Syst Rev; 2002; 2002(1):CD002170. PubMed ID: 11869627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The importance of inhaler devices: the choice of inhaler device may lead to suboptimal adherence in COPD patients.
    Darbà J; Ramírez G; Sicras A; Francoli P; Torvinen S; Sánchez-de la Rosa R
    Int J Chron Obstruct Pulmon Dis; 2015; 10():2335-45. PubMed ID: 26604733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of switching tiotropium HandiHaler® to Respimat® Soft Mist™ Inhaler in patients with COPD: the difference of adverse events and usability between inhaler devices.
    Asakura Y; Nishimura N; Maezawa K; Terajima T; Kizu J; Chohnabayashi N
    J Aerosol Med Pulm Drug Deliv; 2013 Feb; 26(1):41-5. PubMed ID: 22691112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Study of Inhaler Device Handling Technique and Risk Factors for Critical Inhaler Errors in Korean COPD Patients.
    Jang JG; Chung JH; Shin KC; Jin HJ; Lee KH; Ahn JH
    Int J Chron Obstruct Pulmon Dis; 2021; 16():1051-1059. PubMed ID: 33907392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.